

⑪ Publication number:

0 285 287
A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 88302319.4

⑭ Int. Cl.⁵ A61K 31/55

⑮ Date of filing: 17.03.88

⑯ Priority: 23.03.87 US 29289

⑰ Date of publication of application:
05.10.88 Bulletin 88/40

⑱ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑲ Date of deferred publication of the search report:
16.08.90 Bulletin 90/33


⑳ Applicant: SMITHKLINE BECKMAN
CORPORATION
One Franklin Plaza P O Box 7929
Philadelphia Pennsylvania 19103(US)

㉑ Inventor: Bondinell, William Edward
1612 Franklin Lane
Wayne Pennsylvania 19087(US)
Inventor: Ormsbee III, Herbert Stowell
652 Pugh Road
Wayne Pennsylvania 19087(US)

㉒ Representative: Waters, David Martin, Dr. et al
Smith Kline & French Laboratories Ltd.
Patent Department Mundells
Welwyn Garden City Hertfordshire AL7
1EY(GB)

㉓ 3-Benzazepine compounds for use in treating gastrointestinal motility disorders.

㉔ The use of a compound of the formula (I) :



(I)

drogen or C₁-C₆ alkyl; and n is 0, 1 or 2; provided R² is not hydrogen when R³ is S-phenyl in the 6-position and provided that when R² is hydroxy in the 8-position and R¹ is C₁-C₆ alkyl, R³ may be halogen or CF₃ only if it is in the 6- or 9-position.

EP 0 285 287 A3

or a pharmaceutically acceptable acid addition salt thereof, in the manufacture of a medicament for the treatment of gastrointestinal motility disorders is described wherein R¹ is hydrogen, C₁-C₆ alkyl or C₂-C₅ alkenyl; R² is hydrogen, halogen, CF₃, C₁-C₆ alkyl or R⁴O; R³ is hydrogen, CF₃, C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, S-(C₁-C₆) alkyl, S-trifluoromethyl, NO₂, SO₂-phenyl where the phenyl is optionally substituted by hydroxy, C₁-C₆ alkoxy, halogen, CF₃, C₁-C₆ alkyl, SO₂-(C₁-C₆) alkyl, SO₂CF₃, SO₂-phenyl or SO₂NR⁵R⁶; R⁴ is hydrogen, C₁-C₆ alkyl, or C₁-C₆ alkanoyl; R⁵ and R⁶ are hy-



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 30 2319

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
D, X	US-A-4 265 890 (K.G. HOLDEN) * Column 1, lines 8-59; claims 1, 2, 10-13 *	1-13	A 61 K 31/55 C 07 D 223/16
P, X	EP-A-0 216 247 (MERCK & CO. INC.) * Column 1, lines 10-23; claims 1, 2 *	1-13	
P, X	EP-A-0 229 510 (SMITHKLINE BECKMAN) * Page 2, lines 1-38; page 4, line 44 - page 5, line 25; claims *	1-13	
X	CH-A- 498 123 (J.R. GEIGY AG) * The whole document *	10	
Y		1-9, 11-13	
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 9, September 1983, American Chemical Society; R.M. DeMARINIS et al.: "6-Chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine: A potent and selective antagonist of alpha2-adrenoceptors" * The whole document *	1-13	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 23-05-1990	Examiner ORVIZ DIAZ P.
CATEGORY OF CITED DOCUMENTS		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : oral-written disclosure P : intermediate document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : oral-written disclosure P : intermediate document		& : member of the same patent family, corresponding document	